<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565888</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 14.12</org_study_id>
    <nct_id>NCT02565888</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat</brief_title>
  <acronym>DATE-4</acronym>
  <official_title>A Drug-drug Interaction Study Between the Novel Anti-HCV Agent Daclatasvir and the Antiretroviral Agents Atazanavir/Ritonavir or Atazanavir/Cobicistat in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to provide the evidence that 150mg of cobicistat will have the same effect on&#xD;
      the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with&#xD;
      atazanavir 300mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 20-25% of the total number of HIV-infected patients is co-infected with HCV&#xD;
      which translates to 6-8 million persons worldwide. Combined treatment of HIV and HCV is&#xD;
      complicated by the risk of drug-drug interactions as both the direct acting antiviral agents&#xD;
      (DAAs) for HCV as the antiretroviral agents for HIV are substrates of cytochrome P450&#xD;
      (CYP450) or various membrane transporters, and also have the capacity to influence these&#xD;
      systems. A careful selection of the appropriate regimens and if needed adjusted doses is key&#xD;
      for optimal treatment of both viral infections.&#xD;
&#xD;
      Daclatasvir is a recently approved anti-HCV agent that is a CYP3A4 substrate but does not&#xD;
      affect CYP450 itself. It is also a moderate inhibitor of various membrane transporters such&#xD;
      as organic anion-transporting polypeptide (OATP1B1), P-glycoprotein (P-gP), and organic&#xD;
      cation transporters (OCT2).&#xD;
&#xD;
      Atazanavir/ritonavir is one of the preferred antiretroviral agents in all international&#xD;
      guidelines. Ritonavir is used as a boosting agents based on its inhibitory effects on CYP3A.&#xD;
      This also inhibits CYP3A-mediated metabolism of daclatasvir and when atazanavir/ritonavir is&#xD;
      combined with daclatasvir, it is recommended to reduce the dose of daclatasvir from 60mg QD&#xD;
      to 30mg QD.&#xD;
&#xD;
      Cobicistat has recently been approved as an alternative booster of atazanavir at a dose of&#xD;
      150mg QD. It is expected that cobicistat will inhibit CYP3A mediated metabolism of&#xD;
      daclatasvir in a similar manner as ritonavir does, but there are no clinical data to support&#xD;
      this. As cobicistat lacks some of the adverse events associated with ritonavir use, the use&#xD;
      of cobicistat, including as a booster of atazanavir, is likely to increase.&#xD;
&#xD;
      This study aims to provide the evidence that 150mg of cobicistat will have the same effect on&#xD;
      the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with&#xD;
      atazanavir 300mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>adverse events will be collected up to 4 weeks in total (entire study)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Daklinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobicistat</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Tybost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 and not older than 55 years at screening.&#xD;
&#xD;
          2. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at&#xD;
             least 3 months prior to Day 1.&#xD;
&#xD;
          3. Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.&#xD;
&#xD;
          4. Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          5. Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, and electrocardiography, results of biochemistry, hematology and&#xD;
             urinalysis testing within 4 weeks prior to day 1. Results of biochemistry, hematology&#xD;
             and urinalysis testing should be within the laboratory's reference ranges (see&#xD;
             Appendix A). If laboratory results are not within the reference ranges, the subject is&#xD;
             included on condition that the Investigator judges that the deviations are not&#xD;
             clinically relevant. This should be clearly recorded.&#xD;
&#xD;
          6. Subject has a normal blood pressure and pulse rate, according to the Investigator's&#xD;
             judgment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Creatinine clearance below 60mL/min.&#xD;
&#xD;
          2. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.&#xD;
&#xD;
          3. Positive HIV test.&#xD;
&#xD;
          4. Positive hepatitis B or C test.&#xD;
&#xD;
          5. Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1)&#xD;
             or breast-feeding female. Female subjects of childbearing potential without adequate&#xD;
             contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal)&#xD;
             intrauterine device, total abstinence, double barrier methods, or two years&#xD;
             post-menopausal. They must agree to take precautions in order to prevent a pregnancy&#xD;
             throughout the entire conduct of the study.&#xD;
&#xD;
          6. Therapy with any drug (for two weeks preceding Day 1), except for acetaminophen (max 2&#xD;
             gram/day).&#xD;
&#xD;
          7. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular&#xD;
             disorders, neurological disorders (especially seizures and migraine), psychiatric&#xD;
             disorders, gastro-intestinal disorders, renal and hepatic disorders (clinically&#xD;
             relevant increased ALAT/ASAT or hyperbilirubinemia) hormonal disorders (especially&#xD;
             diabetes mellitus), coagulation disorders.&#xD;
&#xD;
          8. Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          9. History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
         10. Inability to understand the nature and extent of the study and the procedures&#xD;
             required.&#xD;
&#xD;
         11. Participation in a drug study within 60 days prior to Day 1.&#xD;
&#xD;
         12. Donation of blood within 60 days prior to Day 1.&#xD;
&#xD;
         13. Febrile illness within 3 days before Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRCN, Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Smolders EJ, Colbers EP, de Kanter CT, Velthoven-Graafland K, Drenth JP, Burger DM. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat. J Antimicrob Chemother. 2017 Feb;72(2):486-489. doi: 10.1093/jac/dkw429. Epub 2016 Oct 20.</citation>
    <PMID>27798211</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HIV</keyword>
  <keyword>atazanavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>daclatasvir</keyword>
  <keyword>cobicistat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

